MA48486B1 - Polymères liant les protons pour administration orale - Google Patents

Polymères liant les protons pour administration orale

Info

Publication number
MA48486B1
MA48486B1 MA48486A MA48486A MA48486B1 MA 48486 B1 MA48486 B1 MA 48486B1 MA 48486 A MA48486 A MA 48486A MA 48486 A MA48486 A MA 48486A MA 48486 B1 MA48486 B1 MA 48486B1
Authority
MA
Morocco
Prior art keywords
proton
oral administration
binding polymers
animal
human
Prior art date
Application number
MA48486A
Other languages
English (en)
Other versions
MA48486A (fr
Inventor
Gerrit Klaerner
Eric F Connor
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Jerry M Buysse
Michael J Cope
Kalpesh N Biyani
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA48486A publication Critical patent/MA48486A/fr
Publication of MA48486B1 publication Critical patent/MA48486B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F271/00—Macromolecular compounds obtained by polymerising monomers on to polymers of nitrogen-containing monomers as defined in group C08F26/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/24—Homopolymers or copolymers of amides or imides
    • C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions pharmaceutiques et méthodes de traitement d'un animal, y compris un être humain, et méthodes de préparation de telles compositions. Les compositions pharmaceutiques contiennent des polymères d'amine réticulés et peuvent être utilisées, par exemple, pour traiter des maladies ou d'autres conditions métaboliques dans lesquelles l'élimination des protons et / ou des ions chlorure du tractus gastro-intestinal fournirait des avantages physiologiques tels que la normalisation des concentrations sériques de bicarbonate et du ph sanguin. Chez un animal, y compris un humain.
MA48486A 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale MA48486B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090287P 2014-12-10 2014-12-10

Publications (2)

Publication Number Publication Date
MA48486A MA48486A (fr) 2020-01-15
MA48486B1 true MA48486B1 (fr) 2021-03-31

Family

ID=55080167

Family Applications (3)

Application Number Title Priority Date Filing Date
MA48486A MA48486B1 (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale

Country Status (26)

Country Link
US (3) US11311571B2 (fr)
EP (4) EP3593808B1 (fr)
JP (5) JP6903576B2 (fr)
KR (3) KR102920551B1 (fr)
CN (2) CN107428955B (fr)
AU (2) AU2015360413B2 (fr)
BR (2) BR112017011838B1 (fr)
CA (4) CA3205149C (fr)
CY (2) CY1122928T1 (fr)
DK (2) DK3229816T3 (fr)
ES (2) ES2787218T3 (fr)
HR (2) HRP20200689T1 (fr)
HU (2) HUE052736T2 (fr)
IL (4) IL322207A (fr)
LT (2) LT3593808T (fr)
MA (3) MA48486B1 (fr)
MD (2) MD3593808T2 (fr)
ME (1) ME03783B (fr)
MX (3) MX377154B (fr)
PL (2) PL3229816T3 (fr)
PT (2) PT3593808T (fr)
RS (2) RS60208B1 (fr)
RU (2) RU2020102937A (fr)
SI (2) SI3229816T1 (fr)
SM (2) SMT202000700T1 (fr)
WO (1) WO2016094685A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
IL262660B2 (en) * 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
EP3698799B1 (fr) 2017-10-16 2022-01-26 FUJIFILM Corporation Agent thérapeutique contre l'hyperphosphatémie
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
CA3080143A1 (fr) * 2017-11-03 2019-05-09 Tricida, Inc. Methode de traitement de troubles de type acide-base
MA51628A (fr) 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236124A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
BR112023017628A2 (pt) * 2021-03-01 2023-12-05 Tricida Inc Composições farmacêuticas de polímero de poli(alilamina) reticulado
SI4053179T1 (sl) 2021-03-01 2026-01-30 Renosis, Inc. Farmacevtski sestavki iz premreženega poli(alilaminskega) polimera

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100164A (ja) * 1987-10-12 1989-04-18 Shionogi & Co Ltd スルファモイル−２−ベンゾフランカルボン酸誘導体
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
EP0786993B1 (fr) 1994-10-17 2002-06-05 Peter W. Stacpoole Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et leur utilisation dans le traitement de troubles metaboliques et cardiovasculaires
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP3952223B2 (ja) * 1997-05-28 2007-08-01 日東紡績株式会社 アリルアミン重合体
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
ES2243016T3 (es) * 1997-12-17 2005-11-16 MERCK & CO., INC. Antagonistas de receptores de integrinas.
WO1999040990A1 (fr) 1998-02-17 1999-08-19 University Of Maryland Polymeres a fixation d'anions et leur utilisation
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
WO2001066607A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant
AU2001241095A1 (en) 2000-03-13 2001-09-24 Hisamitsu Pharmaceutical Co. Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
BR0209020A (pt) 2001-04-18 2004-08-10 Genzyme Corp Composição farmacêutica de polialilamina
CA2444347A1 (fr) 2001-04-18 2002-10-31 Genzyme Corporation Methode pour traiter la goutte et pour fixer l'acide urique
JP2005519949A (ja) 2002-03-11 2005-07-07 ノバルティス アクチエンゲゼルシャフト ナテグリニドの塩
BR0305717A (pt) * 2002-08-02 2004-09-28 Tibotec Pharm Ltd Inibidores da protease do hiv 2-amino-benzotiazol sulfonamida de amplo espectro
EP1597276A4 (fr) 2003-02-10 2006-11-29 Autogen Res Pty Ltd Molecules therapeutiques
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
WO2004113872A2 (fr) * 2003-06-24 2004-12-29 The Trustees Of Columbia University In The City Of New York Procedes covalents d'immobilisation de biomolecules thiolees sur des surfaces siliceuses et metalliques
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
CA2551528A1 (fr) 2003-12-31 2005-07-21 Genzyme Corporation Agents sequestrants des acides biliaires a base de polymeres d'amine aliphatique a revetement gastro-resistant
US20080248012A1 (en) 2004-01-29 2008-10-09 Keio University Erythrocyte Function Modifying Substance
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
KR101153035B1 (ko) 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
PL1771191T3 (pl) 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1898922A4 (fr) 2005-07-04 2012-03-14 Ramu Krishnan Medicament ou composes pharmaceutiques ameliores et preparation associee
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
JP2009510126A (ja) 2005-09-30 2009-03-12 レリプサ， インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
WO2007038801A2 (fr) 2005-09-30 2007-04-05 Ilypsa, Inc. Compositions de liaison aux cations monovalents comprenant des particules coeur-ecorce avec des ecorces polyvinyliques reticulees et procedes pour les utiliser
CN101321519A (zh) 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
EP1946763B1 (fr) 2005-11-08 2013-08-21 Ajinomoto Co., Inc. Agent facilitant le reveil apres une anesthesie
CA2626734A1 (fr) * 2005-11-08 2007-05-18 Genzyme Corporation Polymeres contenant du magnesium pour l'hyperphosphatemie
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) * 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
JP2009536246A (ja) 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
US20100135950A1 (en) 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
US20100124542A1 (en) 2006-07-18 2010-05-20 Genzyme Corporation Amine dendrimers
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
WO2008027551A2 (fr) 2006-09-01 2008-03-06 Genzyme Corporation Compositions de dendrimères
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
EP2441779A1 (fr) 2006-09-01 2012-04-18 USV Limited Procédé pour la préparation d'hydrochlorure de sévélamer et formulation à base de celui-ci
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
BRPI0717545A2 (pt) 2006-09-29 2013-10-22 Gezyme Corp Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida
JP2010513271A (ja) 2006-12-14 2010-04-30 ゲンズイメ コーポレーション アミド−アミンポリマー組成物
US20100129309A1 (en) 2007-02-23 2010-05-27 Dhal Pradeep K Amine polymer compositions
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US20100196305A1 (en) 2007-03-08 2010-08-05 Dhal Pradeep K Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
EP2152277A1 (fr) 2007-04-27 2010-02-17 Genzyme Corporation Compositions dendrimères amido-amine
WO2009005838A2 (fr) 2007-07-02 2009-01-08 Cognate3 Llc Procédé de préparation d'une solution basique non corrosive et ses procédés d'utilisation
JPWO2009008480A1 (ja) 2007-07-11 2010-09-09 東レ株式会社 架橋ポリアリルアミン又はその酸付加塩、及びその医薬用途
EP2016947A1 (fr) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Nouveau processus à une étape pour préparer des polymères poly(allylamine) réticulés
WO2009023544A2 (fr) 2007-08-10 2009-02-19 Ilypsa, Inc. Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
US20090125433A1 (en) * 2007-11-13 2009-05-14 Franck Rene Mikulecz Best pre-match routing (of foreign exchange orders)
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
JP2011506449A (ja) 2007-12-14 2011-03-03 ジェンザイム コーポレーション コーティング医薬組成物
WO2009097127A1 (fr) 2008-01-31 2009-08-06 Genzyme Corporation Compositions pharmaceutiques
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
US20100035992A1 (en) 2008-03-11 2010-02-11 Rajiv Bhushan Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies
BRPI0911041A2 (pt) * 2008-04-08 2016-07-05 Usv Ltd processo para a preparação de sal de polímero de amina
EP2265238B1 (fr) 2008-04-11 2012-01-11 GP Investimenti S.r.l. Pièce à main pour le traitement aux ultrasons de tissu humain
WO2009154747A1 (fr) 2008-06-20 2009-12-23 Genzyme Corporation Compositions pharmaceutiques
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022381A1 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Traitement d'une hyperkaliémie par des polymères d'échange de cation réticulés ayant des propriétés physiques améliorées
WO2010022380A2 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Compositions de polyfluoroacrylate stabilisé par polyol linéaire
BRPI0920515B1 (pt) 2008-09-25 2018-03-20 Vive Nano, Inc. Composição compreendendo nanopartícula de polímero e composto ativo agrícola
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010059384A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
CN103819403B (zh) * 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
US20110081413A1 (en) 2009-01-22 2011-04-07 Ashok Omray Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
CA2777682C (fr) 2009-10-13 2015-02-24 The Regents Of The University Of Michigan Compositions de dendrimeres et procedes de synthese
DK2490675T3 (en) 2009-10-22 2019-04-29 Synthon Bv Pharmaceutical compositions with sevelamer
KR20120103689A (ko) 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
BR112012021448A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
SG11201408521WA (en) 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
ES3059226T3 (en) 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
CN105873583A (zh) 2013-11-04 2016-08-17 凯克斯生物制药公司 用于降低慢性肾病患者的心力衰竭的枸橼酸铁
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CA3080143A1 (fr) 2017-11-03 2019-05-09 Tricida, Inc. Methode de traitement de troubles de type acide-base
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236124A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236639A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
MA51628A (fr) 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
CA3205149C (fr) 2026-02-24
RU2017124157A (ru) 2019-01-10
CN107428955A (zh) 2017-12-01
DK3229816T3 (en) 2020-04-27
IL252439B (en) 2020-10-29
CA2969238C (fr) 2023-10-17
CY1122928T1 (el) 2021-10-29
JP2017538822A (ja) 2017-12-28
US11738041B2 (en) 2023-08-29
RU2017124157A3 (fr) 2019-07-17
MA53106A (fr) 2021-09-15
JP2020158530A (ja) 2020-10-01
EP3718551B1 (fr) 2026-02-04
KR20170095269A (ko) 2017-08-22
LT3229816T (lt) 2020-05-25
EP3229816A1 (fr) 2017-10-18
JP2023085428A (ja) 2023-06-20
JP7258087B2 (ja) 2023-04-14
CN113855703B (zh) 2025-11-25
HUE052736T2 (hu) 2021-05-28
KR102920551B1 (ko) 2026-02-02
MX2017007497A (es) 2017-10-04
AU2015360413B2 (en) 2021-07-08
SMT202000700T1 (it) 2021-01-05
CN107428955B (zh) 2021-09-21
HRP20210204T1 (hr) 2021-03-19
HRP20200689T1 (hr) 2020-07-24
LT3593808T (lt) 2021-02-25
HUE049057T2 (hu) 2020-08-28
DK3593808T3 (da) 2021-02-01
KR20240008418A (ko) 2024-01-18
BR112017011838A2 (pt) 2017-12-26
IL322207A (en) 2025-09-01
MA41150A (fr) 2017-10-18
JP2024164031A (ja) 2024-11-26
ME03783B (fr) 2021-04-20
EP3229816B1 (fr) 2020-02-05
IL290729B2 (en) 2025-12-01
US20220339186A1 (en) 2022-10-27
US20180021370A1 (en) 2018-01-25
ES2787218T3 (es) 2020-10-15
MX377154B (es) 2025-03-07
MD3229816T2 (ro) 2020-07-31
WO2016094685A1 (fr) 2016-06-16
CA3280357A1 (en) 2025-10-30
CA3205149A1 (fr) 2016-06-16
SMT202000225T1 (it) 2020-05-08
EP3593808B1 (fr) 2020-12-09
KR102625115B1 (ko) 2024-01-12
SI3593808T1 (sl) 2021-03-31
RU2713416C2 (ru) 2020-02-05
HK1243952A1 (en) 2018-07-27
PT3593808T (pt) 2021-02-11
JP6903576B2 (ja) 2021-07-14
JP2021176971A (ja) 2021-11-11
MX2021004558A (es) 2022-05-03
AU2021245144A1 (en) 2021-11-04
JP6921276B2 (ja) 2021-08-18
MX382077B (es) 2025-03-13
EP3718551A1 (fr) 2020-10-07
US11311571B2 (en) 2022-04-26
PL3593808T3 (pl) 2021-06-14
IL290729A (en) 2022-04-01
AU2015360413A1 (en) 2017-06-08
CA3164664C (fr) 2025-11-18
MX2019014711A (es) 2020-02-12
CY1124073T1 (el) 2022-05-27
CA2969238A1 (fr) 2016-06-16
MD3593808T2 (ro) 2021-05-31
ES2857177T3 (es) 2021-09-28
RS61409B1 (sr) 2021-03-31
PL3229816T3 (pl) 2020-09-21
US20230405043A1 (en) 2023-12-21
AU2021245144B2 (en) 2024-01-11
MA48486A (fr) 2020-01-15
EP4755931A3 (fr) 2026-07-15
EP3593808A1 (fr) 2020-01-15
EP3718551C0 (fr) 2026-02-04
IL278034A (en) 2020-11-30
KR20260017508A (ko) 2026-02-05
IL252439A0 (en) 2017-07-31
IL290729B1 (en) 2025-08-01
BR122021001914B1 (pt) 2024-02-27
BR112017011838B1 (pt) 2023-04-25
JP7536343B2 (ja) 2024-08-20
PT3229816T (pt) 2020-05-11
CN113855703A (zh) 2021-12-31
SI3229816T1 (sl) 2020-09-30
IL278034B (en) 2022-04-01
MA41150B1 (fr) 2020-06-30
RS60208B1 (sr) 2020-06-30
CA3164664A1 (fr) 2016-06-16
EP4755931A2 (fr) 2026-06-10
RU2020102937A (ru) 2020-02-13

Similar Documents

Publication Publication Date Title
MA48486A (fr) Polymères liant les protons pour administration orale
MY197091A (en) Compositions for treating acid-base disorders
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA34002B1 (fr) Thérapie antivirale
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2008152691A (ru) Способ профилактики и лечения мастита у коров
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
UA111587C2 (uk) Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA38521A1 (fr) Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration
FR3023166B1 (fr) Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire
AR107734A1 (es) Métodos de tratamiento de diarrea en animales no humanos, neonatales y jóvenes, pre-destete
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค